StockIQpro
NASDAQ:SNTI

Senti Biosciences Holdings, Inc.

Track all markets on TradingView
Track all markets on TradingView

Senti Biosciences Holdings, Inc.'s revenue was $22,000 in fiscal 2025. Free cash flow was −$43.6M, −198363.6% of revenue, and the diluted share count rose 389.2%.Summary generated from Senti Biosciences Holdings, Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$22,000
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−312631.8%
Net margin−279263.6%
ROICn/a
Return on equity−393.4%
Debt / equityn/a
Free cash flow−$43.6M
FCF margin−198363.6%
Share count change+389.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue34300
Operating income−40−62−93−61−69
Net income−55−58−71−53−61
Free cash flow−40−76−64−41−44

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)